The CRT Board is delighted to welcome a new Board member, Dr Helga Mikkelsen.
Dr Helga Mikkelsen is WA-based Investment Manager at Brandon Capital, which is Australia and New Zealand’s largest large life science-focused venture capital firm.
Following degrees in Chemical Engineering and Biotechnology, Helga completed her PhD in microbiology at the University of Cambridge and postdoctoral research in bacterial genetics at Imperial College London. She has since focused on the translation and commercialisation of biomedical research discoveries and has worked with early-stage companies developing devices and drug treatments in the UK and Australia.
Helga is a Graduate of the Australian Institute of Company Directors, Director and co-founder of Respirion Pharmaceuticals, and a Board Observer at OncoRes Medical, Catalym and Azura Ophthalmics.
